Selarsdi in Qatar
How patients in Qatar access Selarsdi (seladelpar) via Named Patient Program.
Selarsdi - overview
Selarsdi (seladelpar) is manufactured by CymaBay (now Gilead), verify and indicated for moderate-to-severe plaque psoriasis in adults and pediatric patients 6 years and older, and active psoriatic arthritis in adults. It is a subcutaneous IL-12 / IL-23 p40-inhibitor biosimilar approved by the US FDA in 2024 and may be accessible to patients in Qatar through a Named Patient Program or personal-import pathway.
Access in Qatar
Qatar's MoPH permits unregistered drug import under a named-patient pathway with physician and MoPH approval; Hamad Medical Corp frequently sponsors.
How Reserve Meds coordinates access in Qatar
- Patient or treating physician submits a request.
- We verify clinical appropriateness and Qatar-specific eligibility.
- Treating physician in Qatar issues prescription and clinical justification.
- Country-specific NPP/personal-import forms are prepared and filed.
- We source Selarsdi from a DSCSA-compliant US specialty wholesaler.
- Cold-chain shipment to the patient's physician or hospital pharmacy in Qatar.
Typical timeline for Qatar
End-to-end, most requests are completed in 2-6 weeks. Qatar's tier 2 regulatory maturity typically supports moderate processing times.
What patients and physicians in Qatar ask
- Is the pathway legal in Qatar? Yes - it operates under Qatar's established NPP or personal-import framework.
- Does my insurance cover it? Typically no for NPP drugs; patient prepayment is standard.
- What physician credentials do I need? A licensed physician in Qatar able to issue the prescription and clinical justification.
- What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
- Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.